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Abstract Albumin has a long historical involve-
ment in design of media for the successful culture of
mammalian cells, in both the research and commer-
cial ﬁelds. The potential application of albumins,
bovine or human serum albumin, for cell culture is a
by-product of the physico-chemical, biochemical and
cell-speciﬁc properties of the molecule. In this review
an analysis of these features of albumin leads to a
consideration of the extracellular and intracellular
actions of the molecule, and importantly the role of
its interactions with numerous ligands or bioactive
factors that inﬂuence the growth of cells in culture:
these include hormones, growth factors, lipids, amino
acids, metal ions, reactive oxygen and nitrogen
species to name a few. The interaction of albumin
with the cell in relation to these co-factors has a
potential impact on metabolic and biosynthetic
activity, cell proliferation and survival. Application
of this knowledge to improve the performance in
manufacturing biotechnology and in the emerging
uses of cell culture for tissue engineering and stem
cell derived therapies is an important prospect.
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Introduction
Mammalian cell culture has played an important part
in the advancement of the life sciences over many
decades and more recently has been a key factor in
the application of biomedical research to the devel-
opment of new therapeutic strategies. Cell culture
was a crucial element in the discovery of numerous
hormones, growth factors and other biological factors
essential for understanding physiological processes at
the cellular level and in the whole animal (McKeehan
et al. 1990). In the last decade the beneﬁts of
mammalian cell culture have become increasingly
important for the production of new protein biophar-
maceuticals, including monoclonal antibodies and
cytokines, as well as providing new strategies for
vaccine production (Merten 2006). Tissue engineer-
ing and therapies arising from advances in stem cell
science are broadening the applications for cell
culture technology.
Historically serum has been a crucial component
of cell culture methodology, as a provider of complex
biological molecules such as hormones, growth
factors, attachment factors as well as numerous low
molecular weight nutrients. As an essential medium
component it underpinned the successful growth of a
variety of cell types and in the development of
permanent cell lines. Initially, the requirement for
serum-free media was to allow the culture of primary
cells where the characterization of the biological
molecules present in blood and other biological ﬂuids
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differentiation, to be investigated in a more deﬁned
medium background (Barnes and Sato 1980). The
emergence of industrial scale mammalian cell culture
for the production of protein pharmaceuticals pre-
sented a new challenge for cell culture medium
design, where the question of quality control arose
from the use of foetal bovine serum (FBS). The issues
of reliability of supply and variability in performance
and the risk for biological contaminants (mycoplas-
mas and viruses), created serious safety concerns for
regulatory agencies. In more recent years, the emer-
gence of prion related diseases, speciﬁcally bovine
spongiform encephalomyelitis, led to an increased
demand for deﬁned non-animal sourced medium
components to replace both serum and medium
supplements puriﬁed from animal sources, such as
insulin, transferrin and albumin (Merten 2002).
Early in the development of serum-free media,
bovine serum albumin (BSA) was often incorporated
as an essential component of most media. As the
major protein in FBS, albumin was seen as a
desirable factor associated with successful outcomes
from attempts to grow many cell types and cell lines
in the absence of serum. Often the basis for this result
was never examined, and only rarely was the role it
played in the successful growth of cells established
(Ham 1963; Nilausen 1978). These early develop-
ments and the requirement to address the regulatory
issues surrounding animal-sourced medium compo-
nents resulted in the opportune progression towards
recombinant proteins replacing animal-derived com-
ponents (Keenan et al. 2006).
Albumin is the major protein in serum and is
present typically at around 50 mg/ml, where it makes
up around 60% of the total protein. Approximately
60% of total body albumin is in the extravascular
space, including within the interstitial space of
tissues, which infers an important role in the phys-
iological well-being of cells (Ellmerer et al. 2000).
However, its physiological actions and the molecular
mechanisms involved are not well understood (Quin-
lan et al. 2005; Ahn et al. 2008). Despite this the main
functions of albumin have been summarized to
include (1) maintenance of blood oncotic pressure
and pH (2) binding and transport of physiologically
important ligands, including lipids, metal ions, amino
acids and other factors, and (3) antioxidant functions,
but mainly from the perspective of its role in the
circulation. Clearly these basic functions of the
albumin molecule also apply to the interaction
between albumin and cells in animal tissues, or
importantly for this review, cells grown in culture,
whether in a research laboratory or commercially at
large-scale.
BSA has been more widely used in the develop-
ment of serum-free media than human serum albumin
(HSA) until recently, often due to issues of cost and
supply, rather than for any advantageous functional-
ity (Keenan et al. 1996). In this review of albumins in
cell culture both bovine and human serum-puriﬁed
albumins are considered, as well as more recent work
with recombinant human serum albumin (rHSA)
(Keenan et al. 1997). The actual source of albumin
will be described in each case, although where
appropriate the general term ‘albumin’ will be used.
Applications for albumin are a product of the
physico-chemical, biochemical and cell-speciﬁc
properties of the molecule. Consequently, this review
will address each of these properties in the context of
its potential use as a cell culture medium supplement.
This includes a consideration of (1) structure and
biochemical characteristics of albumin, (2) extracel-
lular actions in the culture medium-including inter-
actions with other substances in the medium, (3)
uptake of albumin into the cell and the processes
involved—including speciﬁc receptors and binding
sites, and the fate of internalised albumin, (4) binding
and carrier functions of albumin—the transport of
lipids, metal ions, and other factors into the cell, (5)
cellular actions of albumin—including anti-oxidant
action and possible roles in metabolic activity, cell
proliferation and survival, and (6) the use of albumin
in industrial cell culture and biopharmaceutical
manufacturing processes.
Structure and biochemical properties
inﬂuencing albumin function
To enable a clearer appreciation of the basis for a
biological function in cells and an application in cell
culture for albumin the unique physico-chemical
properties of the molecule are important. The crystal
structure of HSA reveals a heart-shaped molecule
with 585 amino acids in a single chain that displays
67% a-helix with no b–pleated sheet (He and Carter
1992). The equivalent structures of serum and rHSA
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explaining ligand binding observations for albumin
(Carter and Ho 1994). The dominant feature of the
albumin structure is the three homologous domains
(I, II and III) each made up of two sub-domains (A
and B) with each of these composed of 6 and 4
helices, respectively, each helix being connected by
ﬂexible loops (Fig. 1). The nine loops created by 17
disulphide bridges make up this pattern of three
a-helical domains and one free cysteine, Cys34,
which is buried in an approximately 10A ˚ deep
crevice, which plays a critical role in the redox
properties of albumin. The repeating domain struc-
ture of HSA belies the asymmetry in the binding sites
of different classes of molecules, including lipids and
metal ions, and the importance of this will be
addressed later in relation to its interactions with
cells.
HSA and BSA have been the subjects of extensive
comparative studies for a variety of purposes from
ligand binding to models of protein unfolding and
refolding (Carter and Ho 1994; Hritz et al. 2002;
David et al. 2008). There is no deﬁnitive molecular
structure for BSA from X-ray crystallography or a
solution structure from nuclear magnetic resonance
spectroscopy (NMR), but detailed spectroscopic,
chemical cross-linking and other studies have been
invaluable in trying to determine the 3-D structure of
BSA modelled on the crystal structure of HSA
(Huang et al. 2004). Both albumins share 76%
sequence identity allowing for some differences in
speciﬁc physico-chemical properties, although con-
servation of many, but not all residues characterised
as important for binding various ligands is a feature.
Despite the asymmetric charge distribution within the
primary structure both albumins have approximately
19 negative charges at physiological pH which are
distributed relatively evenly across the surface. The
strong evolutionary conservation of the albumin
sequence across different species infers a critical
role in physiological processes that extends beyond
the functions so far described. Other aspects of the
unique structure of the albumins will be raised where
it inﬂuences their interactions with cells in culture.
Extracellular actions of albumin in the culture
medium
Antioxidant properties of the albumin molecule
The biochemical properties of albumin are responsi-
ble for several important interactions with substances
present in the culture medium that have a direct or
indirect impact on the cell. A key interaction with
cells involves the antioxidant properties of albumin,
and these are relevant to the extracellular environ-
ment of the cell as well as the intracellular compart-
ment. In many ways the role of albumin in the
circulation of mammals, both as an antioxidant and a
transporter of biologically important ligands, serves
as a model for its potential relevance in cell culture.
In the cell culture vessel oxidative stress is created by
reactive oxygen species (ROS) generated by the
interaction of a high oxygen tension, various medium
components and general cell metabolism (Halliwell
and Whiteman 2004). The extracellular environment
of the cell surface as well as the intracellular
compartment is important in terms of risk from
damage due to ROS, especially as it may lack the
regenerating antioxidant mechanisms of the latter
(Roche et al. 2008).
The antioxidant potential of albumin usually
focuses on the sulphur containing amino acids
Fig. 1 Crystal structure of recombinant HSA expressed in
yeast and complexed with the fatty acid myristic acid. The
protein secondary structure is shown schematically (domains
numbered I–III) with the bound myristate molecules shown in
space-ﬁlling representation (carbon, grey; oxygen, red); N and
C represent the N- and C- terminus, respectively. Figure
modiﬁed from Curry et al. (1998)
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are 35 cysteine residues in albumin with all but one
involved in disulphide linkages, leaving, Cys-34, as a
free reduced thiol. While it represents the major
source of free thiols in plasma the overall anti-
oxidative capacity of albumin goes beyond this single
residue. It is now recognized that the antioxidant
capacity of albumin relates largely to its ability to
bind metal ions and to scavenge free radicals as a
substitute substrate, in place of other critical protein,
nucleic acids or lipid moieties. In this role the relative
contribution of Cys-34 and the surface exposed
methionine residues have been assessed (Bourdon
et al. 2005). These authors concluded that in model
systems the antioxidant effect of Cys-34 works
largely through its action as a scavenger of free
radicals, while Met acts mainly as a metal chelator to
reduce subsequent generation of ROS. Other than
these two amino acid residue types, most amino acids
are susceptible to oxidation in the presence of ROS,
and particularly for metal-catalysed oxidation of
proteins, which plays an important role in oxidative
stress (Guedes et al. 2009). Another oxidative product
of Cys-34 involves nitrosylation, a reaction involving
the intracellular messenger nitric oxide (NO) or other
reactive nitrogen species (RNS) generated by the
reaction of NO with superoxide radicals (e.g. O2
-)
(Roche et al. 2008). NO is a vital modulator in most
cellular functions as well as a potential mediator of
cellular damage where excess RNS can oxidize
lipids, DNA and proteins, sometimes leading to cell
death via necrosis or apoptosis (Pacher et al. 2007).
One RNS, peroxynitrite, is generated within the cell
and readily crosses cell membranes, interacts with
target molecules in the medium or cells up to two cell
diameters away (Liaudet et al. 2009). Mostly the role
of RNS in cellular damage has been considered in the
context of intracellular metabolic events, even though
it has the capacity to act beyond the site of generation
to affect other cells.
It is widely acknowledged that albumin provides
protection against lipid peroxidation propagated by
ROS generated by aerobic metabolism, both in vivo
and in vitro (Oettl and Stauber 2007). During this
protective action thiol oxidation at Cys-34 occurs,
indicating the major source of antioxidant protection
afforded by albumin in physiological systems. Bio-
reactors in large scale mammalian cell culture are a
likely environment for generation of oxidative
damage to cells and particularly at the cell surface
interface with the external culture medium. The
presence of dissolved oxygen or of sparged air
bubbles together with medium components, such as
transition metal ions including cuprous (Cu
?1)o r
ferrous (Fe
?2) ions, can give rise to damaging ROS.
When bound to proteins such as HSA or BSA these
metals are much less able to participate in the
catalytic generation of ROS leading to cell damage.
For example, albumin is able to regulate the redox
activity of copper ions by virtue of a high-afﬁnity site
for copper at the N-terminal; if free in solution copper
ions can catalyse the production of free radicals from
oxygen. Moreover, fatty acid binding causes confor-
mational changes to HSA and facilitates the oxidation
of Cys-34. The effect of this is increased redox-
cycling of bound Cu, resulting in an effective
conversion of the Cu/HSA complex from an antiox-
idant to a pro-oxidant, such that it may act itself as a
source of oxidative stress (Gryzunov et al. 2003).
However, in blood, albumin is the second largest
carrier of Cu and co-responsible with ceruloplasmin
for its safe transport and prevention of any detrimen-
tal pro-oxidant activity. As a component in culture
medium albumin would provide the same capability
of protecting against detrimental actions of free Cu
and potentially facilitate its transport into cells. In a
similar manner HSA has the potential to limit
extracellular cell damage caused by redox active
metal ion contaminants in media such as vanadium,
cobalt and nickel (Quinlan et al. 2005).
Few detailed studies exist on the issue of extra-
cellular mediated oxidative stress in bioreactors at
any scale, and the results are often equivocal for the
few evaluating the impact on production of recombi-
nant proteins in industrial cell lines (Dunster et al.
1997). In fact most of the support for the anti-oxidant
role of albumin comes from studies on the circulation
in health and disease, including development of
atherosclerosis, inﬂammation, diabetes and kidney
disease, using animal and cell culture models to
understand the mechanisms involved (Quinlan et al.
2005; Oettl and Stauber 2007). In this context there is
evidence for the role of albumin as an anti-oxidant,
scavenging ROS and RNS generated in the circula-
tion, probably this also applies to the interstitial
spaces of tissues where albumin concentrations are
relatively high compared to blood (Ellmerer et al.
2000). The time frames in bioreactor production runs
4 Cytotechnology (2010) 62:1–16
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apply to development of disease in humans, so it is
unlikely that exactly the same processes are involved
in creating cell stress in the culture of mammalian
cells. Even though the situation for cultured cells is
potentially different, the generation of ROS or RNS
may impact dramatically on cell physiology, includ-
ing topics such as genetic stability or cell viability, as
discussed later.
Effects of albumin mediated by modifying
the extracellular physical environment
The physical environment of the industrial scale
bioreactor in terms of hydrodynamic shear forces and
the possible detrimental impact on mammalian cell
survival or productivity has been widely discussed.
However, these questions still remain largely unan-
swered; although numerous studies have been com-
pleted that provide evidence for understanding the
impact of hydrodynamic forces generated in agitated
and sparged bioreactors (Al-Rubeai et al. 1995;M a
et al. 2002). Recently these and other studies
examining the effect of bubble burst in sparged
reactors have been compared and, indicates that
energy dissipation from typical bioreactor agitation is
well below the threshold that can cause acute cell
death, although it may lead to sub-lethal changes in
cell processes that inﬂuence product composition
(Mollet et al. 2007; Godoy-Silva et al. 2009).
Moreover, bubble rupture following air sparging is
a likely source of cell damage or death, as that event
generates highly damaging stresses at the cell surface
(Chisti 2001; Koynov et al. 2007).
A protective role for albumin against physical
damage in airlift or sparged bioreactors is mentioned
in many publications, but often without any direct
evidence of the exact mechanism involved in cell
death or protection (Hu ¨lscher et al. 1990; Kunas and
Papoutsakis 1990; Smith and Greenﬁeld 1992). It is
clear that mammalian cells differ markedly in their
susceptibility to the hydrodynamic stress in the
bioreactor environment and the ability of albumin
and other additives to provide a protective effect
(Zhang et al. 1995; Chisti 2001). Mammalian cell
damage in sparged bioreactors and the strategies used
to control this damage have been examined by Chisti
(2000). While evidence exists that protein additives
provide protection to animal cells in sparged culture
systems, the exact mechanism by which these addi-
tives protect cells is not clear. For example, in a well
characterised production process using recombinant
BHK-21 cells, in both a 2.5L bubble-free membrane-
aerated bioreactor and a 30L pilot airlift bioreactor,
the addition of 1 g/l albumin (along with 10 mg/l
transferrin and insulin) compared to protein-free
medium, leads to a signiﬁcant reduction of cell lysis,
measured as release of lactate dehydrogenase into the
medium (Hesse et al. 2003). Furthermore, these cell
protective effects of added protein were seen in the
presence of the ‘‘shear protectant’’ Pluronic F68 and
an anti-foaming agent. The concept of utilizing
albumin as a protective agent against the physical
damage arising in a sparged bioreactor appears hard
to sustain, as reported protective effects occur at
protein concentrations that are largely independent of
the effects on ﬂuid turbulence. However, the relative
contributions of physical and physiological effects
are difﬁcult to resolve; despite a recent retrospective
on the topic stating that the protection by medium
additives is now widely accepted to be physiochem-
ical rather than biological in nature (Papoutsakis
2009), the boundary between the two is largely
conceptual. While this apparent distinction may apply
to acute lethal cell damage, the situation with
apoptotic processes and sub-lethal modiﬁcation of
cell physiology is undoubtedly unresolved. It is still
far from clear that protein additives, including
albumin, would not have a beneﬁcial inﬂuence on
cells in the bioreactor environment, however, any
increase in productivity gains would have to stand up
to cost-beneﬁt analysis.
Physical interaction of albumin with the cell
surface
One aspect of an extracellular role for albumin
requires direct binding of albumin to the cell surface.
At the macroscopic level this has been studied in the
biomaterials ﬁeld for medical device applications
where the cell adhesion properties of albumin are of
interest. The switching between non-adhesion and
adhesion of ﬁbroblasts could be achieved by UV
exposure of the albumin coated surface (Yamazoe
et al. 2008; Yamazoe and Tanabe 2008). Other cell
types have shown similar non-adherence to albumin-
coated surfaces, which is at odds with the proposition
that albumin ‘‘protects’’ cells by its non-speciﬁc
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different to the speciﬁc interactions that have been
described at the molecular level between albumin and
cells as discussed below.
Uptake of albumin into the cell and its fate
Pathways controlling the entry of macromolecules
including albumin into cells
Several pathways for entry of macromolecules into
the cell have been described and endocytosis is the
basic cellular process that facilitates this transport. To
understand the potential of albumin, and its bound
ligands, to inﬂuence cell physiology requires an
understanding of the transport processes in different
cell types. Large particles can be taken up by
phagocytosis in specialized cells, and bulk ﬂuid by
macropinocytosis from the surrounding medium, both
of which are relatively major plasma membrane
events involving actin-mediated remodelling of the
plasma membrane. Macropinocytosis is a signal
dependent process stimulated by growth factors
which results in actin-driven formation of rufﬂed
membrane protrusions that fuse with the plasma
membrane resulting in the large endocytic vesicles
(C 1–2 lm); these intracellular vesicles either fuse
with lysosomal vesicles for degradation of their
cargo, or are recycled back to the plasma membrane
surface and released into the medium (Lim et al.
2008). Proteins in the extracellular medium, includ-
ing albumin, are potential cargo for these and other
transport processes that involve endocytosis by
clathrin-dependent or independent mechanisms, here
the membrane vesicles formed are much smaller in
size than in the former modes of entry (Mayor and
Pagano 2007). The complexity of the various endo-
cytic pathways is well illustrated by the latter authors
who proposed a broad classiﬁcation framework for
the clathrin-dependent and independent mechanisms
based on their dependence on the large multi-domain
GTPase, dynamin. Further sub-division is by the
presence of other components including the small
GTPases, CDC42, RhoA or ARF6. The complexity is
further highlighted by the fact that the same protein
cargo, such as albumin, can be internalised by
different mechanism in different cell types, or may
switch pathways within a single cell type under
different conditions.
One widely described endocytic process involves
specialized membrane structures, caveolae; these
membrane domains are involved in clathrin-indepen-
dent endocytosis and contain the proteins caveoli-1
and caveolin-2, which are essential for this dynamin-
dependent pathway. These structures are found
widely in many cell types, such as ﬁbroblasts,
endothelial cells and smooth-muscle cells. Originally
they were thought to be absent in cells of the immune
system, including B-lymphocytes, but expression of
caveolin-1 in this cell type suggests they are likely to
be present, and therefore probably also in hybridoma
cells (Medina et al. 2006). It is beyond the scope of
this review to discuss the different endocytic pro-
cesses in depth other than where it reveals details
about the intracellular transport of albumin. Whatever
the cargo selection process, and the mode of vesicle
formation, the endocytosed cargo is usually trans-
ferred to the early endosomes where preliminary
sorting occurs. Subsequently, the pathway can follow
a recycling route back to the plasma membrane,
passage to the trans-Golgi network or to late endo-
somes and lysosomes for degradation.
Cargo selection mechanisms for transport
into cells
Cargo stimulated signalling pathways are important
in inducing endocytosis, and albumin often employed
as a model substrate, binds to and clusters its
receptor, gp60, into caveolae to activate Gia and
Src kinases, triggering caveolae endocytosis (Conner
and Schmid 2003). Caveolae are widespread in many
cell types and albumin is internalized via caveolae in
human skin ﬁbroblasts and endothelial cells.
Although in CHO cells albumin is internalized by a
clathrin-independent and dynamin dependent process,
it involves a Rho A (GTPase)-dependent mechanism,
rather than involving caveolin-1/2 (Cheng et al.
2006). In other cell types, such as kidney cell lines or
astrocytes, albumin endocytosis involves the mem-
brane glycoprotein megalin, a member of the low-
density lipoprotein receptor family that operates via a
clathrin-dependent process (Caruso-Neves et al.
2006; Bento-Abreu et al. 2008).
The whole question of cargo selection as part of
the uptake process into cells is not well understood in
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ways. In contrast to this are the clathrin-dependent
processes in which speciﬁc adaptor molecules are
involved, often these are well characterised receptors
for ligands such as iron-loaded transferrin, epidermal
growth factor, insulin-like growth factor-I and cho-
lesterol carrying low-density lipoprotein. These high-
afﬁnity receptors and their bound ligands are seques-
tered into coated pits assembled around clathrin
which invaginate into the cell as endocytic vesicles
(Conner and Schmid 2003; Pucadyil and Schmid
2009). Such well-deﬁned speciﬁc receptors and
adaptor proteins to facilitate entry into the cell have
not been described for clathrin-independent pro-
cesses, including those involving caveolae, and the
details remain controversial (Keyel et al. 2006;
Parkar et al. 2009).
One recently characterized receptor for albumin
transport is the neonatal Fc receptor (FcRn) which was
originally characterised as a transport receptor
involved following uptake of maternal IgG, providing
protection against degradation by selective vesicle
recycling back to the cell surface. In a similar fashion
albumin is taken up in a pinocytic mechanism
whereupon FcRn bound albumin in the acidiﬁed
endosomes is recycled to the cell surface, where the
higher physiological pH causes release of the albumin
(Chaudhury et al. 2003;A n d e r s e ne ta l .2006;
Andersen and Sandlie 2009). The rate of albumin
uptake in certain cell types has been measured and in
the epithelial cell line RLE-6TN, where both high and
low-afﬁnity transport systems operate via apparent
clathrin-dependent endocytosis, the transport Vmax
values were 6.5 and 46.9 lg albumin per mg cell
protein per hr, respectively (Tagawa et al. 2008).
These revelations leave largely unanswered the
broader question as to which uptake processes are
important in the different cell types and speciﬁcally for
the cell types utilized for biotechnology applications.
Fate of endocytosed albumin within
different cell types
The pathways following uptake of albumin by the
various endocytic mechanisms are not well charac-
terised; the intracellular sorting processes and ﬁnal
destination of endocytosed albumin for most cell
types has yet to be established. In the Madin-Darby
kidney cell line (MDCK) the mechanism of albumin
uptake, clariﬁed using ﬂuorescently labelled albumin
and clathrin, indicated the co-localization of both
labels within clathrin-coated pits (Erkan et al. 2005).
It is generally accepted that MDCK cells internalize
proteins by both clathrin-dependent and independent
pathways. Moreover, endocytosis via clathrin-coated
pits deliver their cargo to early and late endosomes
that are then transferred to lysosomes for degradation
to amino acids, to be utilized for energy metabolism
or protein synthesis. The fate of albumin in this cycle
is not established except in a few cell types. In the
RLE-6TN alveolar type II epithelial cell line, albu-
min transported by a non-caveolae transport mecha-
nism, predominantly a clathrin-dependent process,
was tracked to lysosomes and the rate of degradation
measured (Yumoto et al. 2006). In the latter study the
apparent uptake of ﬂuorescently labelled albumin was
approximately 1,100 ng/mg cell protein/60 min, in
general agreement with their other measurements in
primary type II and type I rat alveolar epithelial cells
of between 800 and 6,000 ng/mg cell protein/60 min;
the latter is equivalent to 0.2–0.7 pg/cell/60 min
(calculated from: Ikehata et al. 2008; Ikehata et al.
2009). Moreover, ﬂuorimetric analysis after SDS–
PAGE indicated that during this continuous uptake
process approximately 16% of the albumin was
degraded after 60 min. In a cell of different origin,
rat liver endothelial cells, the uptake of a denatured
albumin via gp-18 and gp-30-receptor mediated
caveolae-related endocytosis was of a similar order
(551 ng/mg cell protein/120 min), and also approx-
imately 20% of the ﬂuorescently labelled albumin
was degraded during this period (Bito et al. 2005).
Furthermore, it is interesting to note that the rate of
endocytosis of albumin in these different cell systems
is similar to the maximum export rates of recombi-
nant proteins by exocytosis in cell lines used in
biotechnology processes (&0.4–2.0 pg/cell/60 min).
This poses the question as to whether there is any
common limiting factor in these two different
processes involving generation and movement of
lipid membrane vesicles within the cells lysosomal/
ER-Golgi network. Certainly proteomic and genomic
analysis of the performance of cell culture processes
has provided support for a rate limiting role for the
exocytic process as a whole (Kuystermans et al.
2007).
While the detail of the pathways followed by
albumin taken up by various endocytic mechanisms is
Cytotechnology (2010) 62:1–16 7
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in the capability for albumin transport. Despite this,
the existence of many of the known endocytic
pathways has been established in cells of industrial
relevance including, Chinese Hamster Ovary, mouse
myeloma, hybridoma, PER.C6, the various kidney
derived cell lines, HEK293, MDCK, Vero, Cos, and
BHK-21 cells, to name the most important cell types.
Binding of ligands and carrier-function
of albumin in culture media
Serum albumin has a unique capability to bind a wide
range of endogenous and exogenous ligands, cova-
lently or non-covalently, and this is one of the most
important properties of the molecule in physiological
terms (Carter and Ho 1994). The fact that albumin
binds so many different compounds, such as fatty
acids, metal ions, steroids, amino acids and a variety
of drugs, and combined with its high concentration in
blood and tissues, makes it very important in health
and disease (Peters 1996; Ellmerer et al. 2000).
Pertinent to this review is that at the cellular level the
ability of albumin to interact with the cell surface,
and subsequently the intracellular space, means it
also has the potential to inﬂuence a wide range of cell
processes by the nature of its associated ligand cargo.
Consequently, a discussion of some of the more
important ligands that bind albumin is warranted.
Furthermore, addition of these ligands to the culture
medium or pre-bound to added albumin is relevant to
the discussion of a role for albumin in the bioreactor
performance of industrial cell lines.
Lipid binding to albumin and the effect
on cells in culture
Albuminhaslongbeenknownasthemaincarrierinthe
circulation for delivery of unesteriﬁed fatty acids (FA)
intoandfromtissues.Invivoitincreasesthesolubilityof
long-chain fatty acids (LCFA) by binding between 0.1
and 2 FA molecules per HSA molecule in blood.
Albumin possesses multiple binding sites and a total of
seven binding sites in HSA for medium chain FA, and
saturated, monounsaturated or polyunsaturated long-
chain FA molecules, have been mapped by crystallo-
graphic studies (Petitpas et al. 2001). A recent nuclear
magnetic resonance (NMR) study determined the
relative afﬁnities of all seven heterogeneously distrib-
utedbindingsitesthatprovideinsightsintothepotential
binding interactions of FA and other ligands binding
HSA (Simard et al. 2006) .F a t t ya c i db i n d i n gs t a b i l i z e s
the native and intermediate unfolded states of HSA
during urea and acid induced unfolding, and this
indicates the change in conformational properties of
albumin that arise from its key physiologicalrole in FA
transport.
The molecular mechanisms of FA transport across
the plasma membrane are still largely undeﬁned and it
is likely the predominant transport mechanisms will
be different in different cell types. While the impor-
tance of albumin in the transport of FA has been
known for some time, more recently an active role
rather than a passive role for HSA in the cellular
uptake of LCFA has been promoted with evidence for
direct albumin interaction with the cell surface
(Trigatti and Gerber 1995: Abumrad et al. 2000).
Moreover, this process involves sequential transfer
with initial dissociation of FA from albumin in
conjunction with membrane bound FA-binding pro-
teins including FAT/CD36 (Ehehalt et al. 2006). The
latter are associated with cholesterol/sphingolipid
dependent lipid rafts on the plasma membrane that
facilitate the uptake process into the cell (Stremmel
et al. 2001; Ehehalt et al. 2006). It is also proposed
that these proteins mediate the dissociation of FA
from albumin; moreover, these proteins facilitate the
translocation in association with endoplasmic and
mitochondrial enzymes catalysing FA esteriﬁcation
involving acyl-coA synthetases (Milger et al. 2006;
Ehehalt et al. 2008).
The function of serum albumin in cholesterol
transfer between ﬁbroblast cells and lipoproteins is
well studied, as it is for endothelial cells, due to its
central role in coronary vascular disease and athero-
sclerosis(Zhao and Marcel 1996; Ha et al. 2003). This
isanimportantfunctionforalbumininmanycelltypes
and particularly for cholesterol dependent cell lines
such as NS0 myeloma and derivative hybridoma cells.
The association of steroids with albumin has not been
extensively studied, possibly due to the charge
neutrality of many endogenous steroids which as a
result have low afﬁnity for albumin, with binding
constants (Kd) of between 10
-6 and 10
-4, although
this is increased after binding the FA, palmitate.
Furthermore, albumin may modulate the biological
actionofsteroidsoncells(AmundsenandSire ´n2007).
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lators of cell physiology is widely available and the
importance of this for industrial cell culture in the
development of serum-free media has been long
recognized (Merten 2002). Depending on the cell
type, a differential response in cell growth may be
observed with media containing either recombinant
HSA, serum-derived fraction V or fatty-acid free
serum-derived HSA. Many studies looking at the role
of albumin have employed these various sources of
albumin, which due to different production processes
and hence impurities or modiﬁcations of the albumin,
often makes it difﬁcult to draw ﬁrm conclusions
(Castro et al. 1996). The complexity of this issue is
seen with the recent identiﬁcation of 141 different
proteins in commercial human serum albumin prep-
arations using a proteomics approach (Gay et al.
2010). However, a few of the many examples of cell
responses to albumin with bound lipid follows:
(i) Human serum-borne albumin lipids promote
cellular survival after apoptosis induction
(Schiller et al. 2008)
(ii) Human serum albumin mediates cholesterol
efﬂux from cultured endothelial cells (Ha et al.
2003)
(iii) Recombinant HSA and fatty acid-free HSA
show slight stimulation of some cell lines but
not others (Keenan et al. 1997)
(iv) Albumin-associated lipids regulate human
embryonic stem cell self-renewal (Garcia-
Gonzalo and Belmonte 2008)
(v) The anti-apoptotic activity of albumin for endo-
thelial cells is independent of free radical
scavenging and bound lipid but acts via a G-
coupled PI3 K-dependent mechanism (Bolitho
et al. 2007)
(vi) Stimulationofkidneycellapoptosisbyalbumin-
bound fatty acids mediated by the peroxisome
proliferator activated receptor-c (Arici et al.
2003)
(vii) Effects of endogenous ligands on the biological
role of human serum albumin in S-nitrosylation
(Ishima et al. 2007)
(viii) Separation of growth-stimulating activity of
BSA fraction V from the bulk of albumin
using Heparin Sepharose Chromatography
(Keenan et al. 1996)
Albumin has enormous potential to modulate the
functioning of cells via its capacity to bind lipids and
facilitate entry into the cell. It is not clear from the
literature how this property could be best utilized to
improve the biomedical and manufacturing applica-
tions of mammalian cells. However, it does provide
some strong research directions to pursue for
potential applications utilizing the lipid binding
characteristics of HSA in the industrial bioreactor,
tissue engineering and stem cell production
processes.
Metal ion binding and intracellular actions
Two high-afﬁnity metal binding sites on albumin
have been characterized by a variety of spectroscopic
and chemical means (Carter and Ho 1994). The
location for binding of Cu
?2 and Ni
?2 involves the
ﬁrst three residues of the N-terminus, Asp-Ala-His,
with His being critical for the observed high-afﬁnity
binding for Cu
?2,K d= 1p M( R o ´zga et al. 2007).
The second metal-binding site involves the free
sulphydryl of HSA, Cys-34. In this case the cysteine
thiol is essential for high-afﬁnity binding of Cd, Au,
Hg and Ag. Weaker binding afﬁnities exist for Ca,
Mn, Zn and Fe ionic species, with afﬁnities decreas-
ing in that order. The two contrasting aspects of
metals in biology are the requirement for metals as
essential co-factors in numerous biological systems
and their toxic effects when exposed to sensitive
biological processes. Interaction of albumin with
various metals means it can play a dual role in both
these situations, and some beneﬁcial aspects of a role
for albumin in cell culture are considered here.
Although there is considerable interest in the
potential role of Cu
?2 ions in human health, such as
neurodegenerative conditions, little is known about
the delivery of copper into mammalian cells and the
role albumin may play in these processes. Most of the
studies on albumin-copper interactions are in cell
culture models of human diseases. A recent publica-
tion investigated the uptake of copper bound to two
human serum-derived proteins, HSA and a2-macro-
globulin, by human hepatic and mammalian epithelial
cell lines. Uptake kinetics were more complex for
Cu-albumin and differed for both cell types studied,
suggesting more than one transport mechanism, and
these did not include either the ubiquitous copper
Cytotechnology (2010) 62:1–16 9
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cation transporter, DTM1 (Moriya et al. 2008).
HSAisalsothe mainzincbindingproteininplasma
where98%oftheavailablezincinthebodyisboundto
serum albumin. Although binding with lower afﬁnity
than Cu
?2, it still has an equilibrium binding constant
ofK & 10
7 M
-1,whichindicatesthepotentialimpor-
tance of Zn in biological systems where it is an
essential metal co-factor required for numerous extra-
cellular andintracellular proteinsandenzymes.Onthe
basis of NMR studies, site-directed mutagenesis and
molecular modelling, the major Zn binding site on
albumin is located at the interface of domains I and II,
andisformedbythesidechainsofHis67andAsn99of
domain I in conjunction with His247 and Asp249 of
domainII(Blindaueretal.2009).Variousstudieshave
identiﬁed an involvement of albumin binding in the
transport of Zn across the plasma membrane of cells,
including endothelial cells, where early studies sup-
ported the existence of two major pathways for
transcytosis, a receptor mediated endocytosis involv-
ing recognition of the Zn-albumin complex and co-
transport involving macropinocytosis (Tibaduiza and
Bobilya 1996). More recently the same authors exam-
ined the uptake into endothelial cells of Zn and
albumin, where endocytosis in a 1:1 stoichiometry
suggested co-transport with albumin via receptor-
mediated endocytosisasthephysiologicalrouteforZn
delivery (Rowe and Bobilya 2000). Zinc has been
proposedasareplacementforthegrowthfactorinsulin
in hybridoma, myeloma NS0 and Chinese hamster
ovary cell culture, to create a more chemically deﬁned
cell culture medium (Wong et al. 2004, 2006). The Zn
binding and transport capabilities of albumin were not
utilizedin these latter studies and may further improve
the effectiveness of Zn to stimulate cell growth and
productivity in these industrially relevant cell lines.
Othermetalinteractionswithalbuminareofspecial
interest,includingvanadiumandvanadium-containing
pharmaceutical compounds. Vanadium compounds
are known to have insulin-mimetic properties and
have been trialled for the treatment of type II diabetes.
The mechanism of action is not entirely clear, but
recent studies suggest an effect on membrane lipids
involved in insulin-receptor signalling, and the inhibi-
tion of protein-kinase phosphatases that enhance
signalling from the insulin receptor substrate (IRS)-1,
phosphatidylinositol 3-kinase (PI3-K) and phosphoki-
nase B (PKB/Akt) cascades (Huyer et al. 1997; Mehdi
et al. 2006; Roess et al. 2008). In cultured cells and in
vivo models of vanadium action on these pathways,
albumin binding and co-transport was an important
factor (Makinen and Brady 2002;L i b o i r o ne ta l .2005).
Thissuggeststhatfurtherusecouldbemadeoftheknown
value of vanadium as a trace element in cell growth.
Selenium is widely used as an essential growth
promoting agent in cell culture media e.g. insulin/
transferrin/selenium (ITS). Despite some early stud-
ies that suggest plasma transport of selenium is
facilitated by albumin, whereas its intracellular
transport is mediated by speciﬁc seleno-binding
proteins, the full details of the selenium biological
cycle are not known (Sani et al. 1988). Recently
albumin-mediated selenium transfer by a selenotri-
sulphide relay mechanism into cells suggests a
potential role for optimizing the beneﬁcial actions
of selenium in combination with human serum
albumin in medium design (Haratake et al. 2008).
A potential role for albumin in facilitating the
uptake and action of essential metals in cell growth
leading to improvements in both cell-based applica-
tions, and the production of recombinant proteins
from mammalian cells is clearly supported.
Cellular actions of albumin
Antioxidant actions of albumin in cells
Few studies have examined the intracellular redox
processes that occur in which protein thiolation and
dethiolation reactions potentially interact with the
established glutathione/glutaredoxin system (Di Sim-
plicio et al. 2005). Most of the studies in this area of
redox chemistry have been carried out in vitro in
model systems using albumin as the archetypal
protein to clarify the mechanisms that may be
involved within the cell or in plasma (Summa et al.
2007). As already discussed, very little exact infor-
mation exists about the intracellular fate of albumin,
except in the case of the FcRn receptor, consequently,
any intracellular redox role for albumin, comparable
to its extracellular role in the circulation, is unknown.
Direct action of albumin on cells in culture
Albumin or modiﬁed albumins have an important role
in relation to disease mechanisms in human health
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heart disease. Cell culture models of the mechanisms
by which albumin may play a role in development of
these conditions provide an opportunity to gain
insight into the possible actions of albumin on cells
from a biotechnology perspective. This is especially
so when the commercially relevant cell lines share
the same tissue or embryonic developmental origin.
For example, kidney derived cells such as MDCK,
Vero, HEK-293 and BHK-21 cells have been used
extensively for vaccine or recombinant protein
expression and some of these cells, particularly
MDCK cells have been widely used as a model for
studying aspects of kidney disease. In studies using
MDCK cells as a model for distal tubule cells of the
kidney, human serum albumin stimulated net cell
proliferation; speciﬁcally, total cell turnover was
stimulated i.e. both cell proliferation and late onset
apoptosis (Erkan et al. 2005). Of interest in the same
study with HKC-8 cells of proximal kidney origin,
albumin incubation induced marked cytotoxicity,
which was closely related to the fatty acid content
of the albumin as observed with other proximal
kidney derived cell lines (Takase et al. 2008).
Likewise there have been a number of studies on
the effect of albumin on endothelial cell lines due to
the potential importance of albumin mediated effects
in vascular disease in humans. In contrast to the often
reported apoptotic effects in some kidney cell lines,
albumin is anti-apoptotic in endothelial cells of
vascular origin, and the latter effects appear inde-
pendent of its ROS scavenging properties or bound
lipid (Bolitho et al. 2007). One issue in many studies
on both kidney and vascular endothelial cells is the
effect of glycation of albumin, as occurs mostly in
diabetes for example, and which universally results in
greater cytotoxicity of albumin. As little as one glycyl
moiety per molecule was sufﬁcient to dramatically
increase the toxicity of albumin. The implications
are, whether the albumin is sourced from serum or
made by a recombinant process, for industrial and
biomedical cell culture applications the presence of
carbohydrate adducts should be avoided.
The beneﬁcial effects of albumin in primary cell
culture and stem cell culture are often mentioned.
Improved functionality for cultured mouse and
human pancreatic islets was observed when incubated
with bovine or human serum albumin, respectively
(Barbaro et al. 2008; Zawalich and Zawalich 2008).
There are beneﬁcial effects of albumin in cell culture
resulting from its interactions with other biological
factors such as insulin, epidermal growth factor
(EGF) or as a carrier of the intracellular signalling
molecule, nitric oxide (Ishima et al. 2008). In retinal
precursor cells albumin augmented their proliferation
in association with EGF and this suggests the
commercial cell line Per.C6
TM, derived from human
embryonic retinal cells, may beneﬁt from media
containing a combination of these factors (Yang et al.
2009). In the case of stem cells, cell-based tissue
engineering, and mammalian cell produced protein
therapeutics, the requirement for a recombinant form
of human serum albumin may offer culture perfor-
mance beneﬁts, and certainly would address many of
the regulatory concerns arising from the use of
animal sourced medium components (Carpenter et al.
2009). For example, cell microencapsulation for
biomedical applications requires approved materials,
and it has been concluded that HSA may be a
possible substitute for FBS to support cells in alginate
–polyL-lysine-alginate capsules prior to implantation
(De Castro et al. 2006). Moreover, medium design for
stem cell and tissue-engineering applications is
undergoing rapid development and rHSA is a valu-
able supplement in this endeavour.
The most recent examples of the use of albumin in
cell culture come mostly from stem cell applications,
such as providing a crucial ingredient in media to
support the reproducible differentiation of human
embryonic stem cells (hESC) in response to added
growth factors. In this role, recombinant HSA, added
at 5 mg/ml, is a more reliable and uniform medium
component than serum-puriﬁed BSA and provides a
robust platform for hESC differentiation (Ng et al.
2008; Hatzistavrou et al. 2009). The culture of hESCs
in serum-free, feeder-cell-free conditions requires the
use of albumin in the medium, and recombinant HSA
meets both this need and the regulatory requirements
essential for future clinical applications (Manton
et al. 2010). Similarly, there is an increasing interest
in albumin for use in culture media in tissue repair
and engineering applications; particularly for recom-
binant HSA, which can provide the platform for
serum-free media, such as in the development of
keratinocyte and ﬁbroblast co-culture in skin equiv-
alent strategies (Mujaj et al. 2010). It is widely
recognized that the development of large scale
processes for the generation of hESCs, induced
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derivatives, will be necessary before stem cell-based
therapies become widespread in the clinic (Kehoe
et al. 2010). Consequently, the availability of reliable
sources of high-quality recombinant albumin appears
to be an important requirement for achieving these
goals.
Applications in large-scale bioreactors
Accounts of albumin use at industrial scale in the
literature are limited and lacking detailed analysis.
Indeed most of the thinking in this area has centred
on ﬁnding replacements for serum-derived bovine or
human albumin and to provide some of the ‘‘beneﬁts’’
delivered by these preparations; as the former
retained ‘‘unknown factors’’ from blood in their ﬁnal
puriﬁed forms (Keenan et al. 1997; Merten 2002).
Historically the inclusion of albumin in serum-free
media was viewed as desirable, but insufﬁcient
evaluations have been undertaken to establish a clear
beneﬁt for its inclusion. This was partly illustrated in
the report of Hesse et al. (2003) discussed earlier,
they employed BHK-21 cells and chemically-deﬁned
protein-free media versus media containing 1 mg/ml
albumin. Although improvements in cell stability
were observed at the 2.5 and 20 L scale, no
signiﬁcant improvement in cell speciﬁc production
of interleukin-2 was observed in the presence of the
protein additives at all scales, including at the
1,000 L scale, although only one run was completed
at the larger scale.
Growth and monoclonal antibody production by
hybridoma cells is stimulated by the addition of
0.5 mg/ml to 5 mg/ml of serum-puriﬁed albumin to
serum-free media, and albumin is included in a list of
recommended components for commercial hybrid-
oma media (Glassy et al. 1988). Although, during the
following decade the availability of only serum-
puriﬁed HSA or BSA, rather than a recombinant
source, was an important reason for non-inclusion of
albumin in medium design, due to the regulatory and
other constraints associated with serum-sourced
albumins. Proliferation and production of monoclonal
antibody by Sp2/0 hybridoma cells in both a 50 ml
tube scale-down model and 2.5 L bioreactor system
are stimulated equally by the addition of either native
puriﬁed BSA or recombinant HSA (L. Chirkova and
K. Bertram personal communication). Commercially,
three marketed monoclonal antibodies produced in
hybridomas, Erbitux and Remicade, in Sp2/0 cells,
and Zenapax in NS0 cells, further indicate that in
principle an opportunity exists for recombinant HSA
containing media (Stadlmann et al. 2008). While the
development of serum-free media for viral vaccine
production has involved lengthy consideration of the
need to replace the beneﬁts gained from inclusion of
HSA or BSA in medium formulations, the answers to
this challenge are complex (Merten 2002).
Concluding remarks
Albumin has been widely used in cell culture over the
last few decades as a component in serum free media,
mainly due to its role as an important carrier of
‘serum-derived’ substances that support mammalian
cell growth. These include lipids, amino acids,
hormones, peptides, metals and other undeﬁned low
molecular weight molecules. Is this carrier function
essential or advantageous for most cell types and
speciﬁcally those employed in biomedical and bio-
pharmaceutical manufacturing? Currently the answer
in most cases is that it is not essential, but in many
situations it may offer improved cell performance,
based on the properties discussed here. Furthermore,
the situation may be more encouraging if the
emerging cell based therapies in tissue engineering,
including use of stem cells, are considered. There is
considerable scope to utilize albumin as a carrier of
bioactive small molecules, or co-factors, including
metal ions. The role of albumin in the function of
these bioactive molecules in improving cell growth
and performance is unlikely to be absolute; however,
it has been shown that albumin contributes to the
efﬁcacy of many of these molecules in improving cell
growth and survival. At this stage, it must be
remembered that most of the effects of albumin have
been carried out in small scale cell culture, rather
than in large-scale bioreactors or more valid scaled
models. It is well established that it is at industrial
scale, where cells are producing large quantities of
recombinant protein, they are under most physical
and metabolic stress. Hence, it is in the industrial
scale situation where the beneﬁcial role of albumin
would be expected to be seen. Currently, there is a
strong move towards chemically-deﬁned and even
12 Cytotechnology (2010) 62:1–16
123protein-free media, including the avoidance of ani-
mal-free but complex hydrolysates. This position
impacts on how albumin is perceived, despite its
production to similar process standards as the
recombinant products being manufactured for the
clinic. The wide-spread inclusion of recombinant
albumins in media for large-scale recombinant pro-
duction will depend on the speciﬁc application, where
cost-beneﬁt analysis is favourable, and is more likely
to be included in cell-based vaccine production. The
situation is more encouraging for the production of
cells or related products for tissue engineering and in
stem cell–cell therapy, where the cost-structures are
different, and some of the beneﬁcial properties of
albumin described in this review may be critical to
developing a successful therapeutic product.
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